A Self‐Amplifying ROS‐Responsive Nanoplatform for Simultaneous Cuproptosis and Cancer Immunotherapy
Advanced Science · 2024-06 · 11 (23)
DOI: 10.1002/advs.202401047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.04.2024. Verfasst von Hangyi Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Immunotherapy, Copper. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Six Talent Peaks Project in Jiangsu Province, Program for Jiangsu Provincial Excellent Scientific and Technological Innovation Team, National Science and Technology Major Project.
Abstract (Originalsprache)
Cuproptosis is an emerging cell death pathway that depends on the intracellular Cu ions. Elesclomol (ES) as an efficient Cu ionophore can specifically transport Cu into mitochondria and trigger cuproptosis. However, ES can be rapidly removed and metabolized during intravenous administration, leading to a short half‐life and limited tumor accumulation, which hampers its clinical application. Here, the study develops a reactive oxygen species (ROS)‐responsive polymer (PCP) based on cinnamaldehyde (CA) and polyethylene glycol (PEG) to encapsulate ES‐Cu compound (EC), forming ECPCP. ECPCP significantly prolongs the systemic circulation of EC and enhances its tumor accumulation. After cellular internalization, the PCP coating stimulatingly dissociates exposing to the high‐level ROS, and releases ES and Cu, thereby triggering cell death via cuproptosis. Meanwhile, Cu 2+ ‐stimulated Fenton‐like reaction together with CA‐stimulated ROS production simultaneously breaks the redox homeostasis, which compensates for the insufficient oxidative stress treated with ES alone, in turn inducing immunogenic cell death of tumor cells, achieving simultaneous cuproptosis and immunotherapy. Furthermore, the excessive ROS accelerates the stimuli‐dissociation of ECPCP, forming a positive feedback therapy loop against tumor self‐alleviation. Therefore, ECPCP as a nanoplatform for cuproptosis and immunotherapy improves the dual antitumor mechanism of ES and provides a potential optimization for ES clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China.
- Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210023, China.
- Department of Pharmaceutics, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, 223800, China.
ORCID-Profile: Huixia Lv
Förderung
- Six Talent Peaks Project in Jiangsu Province
- Program for Jiangsu Provincial Excellent Scientific and Technological Innovation Team
- National Science and Technology Major Project
- National Natural Science Foundation of China
Zitieren
APA
Wu, H., Zhang, Z., Cao, Y., Hu, Y., Li, Y., Zhang, L., Cao, X., Wen, H., Zhang, Y., Lv, H., & Jin, X. (2024). A Self‐Amplifying ROS‐Responsive Nanoplatform for Simultaneous Cuproptosis and Cancer Immunotherapy. Advanced Science, 11(23). https://doi.org/10.1002/advs.202401047
Vancouver
Wu H, Zhang Z, Cao Y, Hu Y, Li Y, Zhang L, et al. A Self‐Amplifying ROS‐Responsive Nanoplatform for Simultaneous Cuproptosis and Cancer Immunotherapy. Advanced Science. 2024;11(23). doi:10.1002/advs.202401047
BibTeX
@article{Wu2024,
author = {Wu, Hangyi and Zhang, Zhenhai and Cao, Yanni and Hu, Yuhan and Li, Yi and Zhang, Lanyi and Cao, Xinyi and Wen, Haitong and Zhang, Youwen and Lv, Huixia and Jin, Xin},
title = {A Self‐Amplifying ROS‐Responsive Nanoplatform for Simultaneous Cuproptosis and Cancer Immunotherapy},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {23},
doi = {10.1002/advs.202401047}
}
EUVIMED